# Cognition and HRQoL in Adults With Highly-active RMS in Year 3 and 4 After Initial Mavenclad® Dose (CLARIFY MS Extension)

> **NCT04776213** · PHASE4 · COMPLETED · sponsor: **Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany** · enrollment: 280 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** Mavenclad®

## Key facts

- **NCT ID:** NCT04776213
- **Lead sponsor:** Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-02-23
- **Primary completion:** 2023-06-20
- **Final completion:** 2023-06-20
- **Target enrollment:** 280 (ACTUAL)
- **Last updated:** 2024-05-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04776213

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04776213, "Cognition and HRQoL in Adults With Highly-active RMS in Year 3 and 4 After Initial Mavenclad® Dose (CLARIFY MS Extension)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04776213. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*